Results 101 to 110 of about 28,560,894 (288)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

, 2018
Francesco Giorgino,1 Alfred Penfornis,2 Valeria Pechtner,3 Raffaella Gentilella,4 Antonella Corcos4 1Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari ...
Corcos A, Penfornis A, Pechtner V, Giorgino F, Gentilella R   +4 more
core  

Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]

, 2011
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen), Waugh, Norman, Shyangdan, D. (Deepson), Royle, Pamela, HASH(0x55a67fac50c0)   +4 more
core  

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

, 2015
Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-
Shyangdan DS, O’Hare JP, Gurung T, Waugh N   +3 more
core  

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source

Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro‐Eating Disorder Community on X (Formerly Twitter)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are complex conditions with medical and psychosocial implications. Social media (SM) exposure has been associated with increased body image concerns and maladaptive eating behaviors. Pro‐eating disorder (pro‐ED) communities exist across SM platforms and often perpetuate ED‐related identities and behaviors.
Daisy Sun, Tovah Yanover, Helena Katona, Jennifer Couturier   +3 more
wiley   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source